APO Research
Talk to an analyst

APO RESEARCH · REPORT

Escitalopram

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Escitalopram Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025195 pages

Choose your research edition.

Industry ResearchEscitalopram Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Escitalopram Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Escitalopram Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Escitalopram Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Escitalopram Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Escitalopram market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Escitalopram is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Escitalopram is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Escitalopram is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Escitalopram is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Escitalopram include Accord Healthcare (IN), Amneal Pharmaceuticals (US), Apotex (CA), Aurobindo Pharma (IN), Forest Laboratories (US), Hetero Drugs (IN), Hikma Pharmaceuticals (UK), Hunan Dongting Pharmaceutical (CN) and Jewim Pharmaceutical (Shandong), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Escitalopram market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Escitalopram and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Escitalopram sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Escitalopram market size, projected growth trends, production technologies, key applications, and end-use industries.

Escitalopram Segment by Company

Accord Healthcare (IN)

Amneal Pharmaceuticals (US)

Apotex (CA)

Aurobindo Pharma (IN)

Forest Laboratories (US)

Hetero Drugs (IN)

Hikma Pharmaceuticals (UK)

Hunan Dongting Pharmaceutical (CN)

Jewim Pharmaceutical (Shandong)

Lundbeck (DK)

Lupin (IN)

Macleods Pharmaceuticals (IN)

Silarx Pharmacueticals (US)

TEVA (Israel)

Xidian Pharmaceutical (CN)

Zhejiang Conba Pharmaceutical (CN)

Mylan (US)

Novartis (US)

Sichuan Kelun Pharmaceutical (CN)

Xian Janssen Pharmaceutical (CN)

Zhejiang Huahai Pharmaceutical (CN)

Escitalopram Segment by Type

Tablets

Solution

Escitalopram Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Escitalopram Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Escitalopram market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Escitalopram and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Escitalopram.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Escitalopram market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Escitalopram manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Escitalopram in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Escitalopram in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Escitalopram Industry Trends Table 2. Escitalopram Industry Drivers Table 3. Escitalopram Industry Opportunities and Challenges Table 4. Escitalopram Industry Restraints Table 5. Global Escitalopram Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Escitalopram Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Escitalopram Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Escitalopram Sales Market Share by Manufacturers Table 9. Global Escitalopram Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Escitalopram Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Escitalopram Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Escitalopram Manufacturers, Product Type & Application Table 13. Global Escitalopram Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Escitalopram by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tablets Table 17. Major Manufacturers of Solution Table 18. Global Escitalopram Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Escitalopram Sales by Type (2021-2026) & (K Units) Table 20. Global Escitalopram Sales by Type (2027-2032) & (K Units) Table 21. Global Escitalopram Sales Market Share by Type (2021-2026) Table 22. Global Escitalopram Sales Market Share by Type (2027-2032) Table 23. Global Escitalopram Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Escitalopram Revenue by Type (2021-2026) & (K Units) Table 25. Global Escitalopram Revenue by Type (2027-2032) & (K Units) Table 26. Global Escitalopram Revenue Market Share by Type (2021-2026) Table 27. Global Escitalopram Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Retail Pharmacies Table 29. Major Manufacturers of Online Pharmacies Table 30. Major Manufacturers of Hospital Pharmacies Table 31. Global Escitalopram Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Escitalopram Sales by Application (2021-2026) & (K Units) Table 33. Global Escitalopram Sales by Application (2027-2032) & (K Units) Table 34. Global Escitalopram Sales Market Share by Application (2021-2026) Table 35. Global Escitalopram Sales Market Share by Application (2027-2032) Table 36. Global Escitalopram Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Escitalopram Revenue by Application (2021-2026) & (K Units) Table 38. Global Escitalopram Revenue by Application (2027-2032) & (K Units) Table 39. Global Escitalopram Revenue Market Share by Application (2021-2026) Table 40. Global Escitalopram Revenue Market Share by Application (2027-2032) Table 41. Global Escitalopram Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Escitalopram Sales by Region (2021-2026) & (K Units) Table 43. Global Escitalopram Sales Market Share by Region (2021-2026) Table 44. Global Escitalopram Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Escitalopram Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Escitalopram Sales by Country (2021-2026) & (K Units) Table 48. North America Escitalopram Sales by Country (2027-2032) & (K Units) Table 49. Europe Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Escitalopram Sales by Country (2021-2026) & (K Units) Table 51. Europe Escitalopram Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Escitalopram Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Escitalopram Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Escitalopram Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Escitalopram Sales by Country (2027-2032) & (K Units) Table 58. Global Escitalopram Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Escitalopram Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Escitalopram Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Escitalopram Revenue Market Share by Region (2021-2026) Table 62. Global Escitalopram Revenue Market Share by Region (2027-2032) Table 63. Accord Healthcare (IN) Company Information Table 64. Accord Healthcare (IN) Business Overview Table 65. Accord Healthcare (IN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Accord Healthcare (IN) Escitalopram Product Portfolio Table 67. Accord Healthcare (IN) Recent Development Table 68. Amneal Pharmaceuticals (US) Company Information Table 69. Amneal Pharmaceuticals (US) Business Overview Table 70. Amneal Pharmaceuticals (US) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Amneal Pharmaceuticals (US) Escitalopram Product Portfolio Table 72. Amneal Pharmaceuticals (US) Recent Development Table 73. Apotex (CA) Company Information Table 74. Apotex (CA) Business Overview Table 75. Apotex (CA) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Apotex (CA) Escitalopram Product Portfolio Table 77. Apotex (CA) Recent Development Table 78. Aurobindo Pharma (IN) Company Information Table 79. Aurobindo Pharma (IN) Business Overview Table 80. Aurobindo Pharma (IN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Aurobindo Pharma (IN) Escitalopram Product Portfolio Table 82. Aurobindo Pharma (IN) Recent Development Table 83. Forest Laboratories (US) Company Information Table 84. Forest Laboratories (US) Business Overview Table 85. Forest Laboratories (US) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Forest Laboratories (US) Escitalopram Product Portfolio Table 87. Forest Laboratories (US) Recent Development Table 88. Hetero Drugs (IN) Company Information Table 89. Hetero Drugs (IN) Business Overview Table 90. Hetero Drugs (IN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hetero Drugs (IN) Escitalopram Product Portfolio Table 92. Hetero Drugs (IN) Recent Development Table 93. Hikma Pharmaceuticals (UK) Company Information Table 94. Hikma Pharmaceuticals (UK) Business Overview Table 95. Hikma Pharmaceuticals (UK) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio Table 97. Hikma Pharmaceuticals (UK) Recent Development Table 98. Hunan Dongting Pharmaceutical (CN) Company Information Table 99. Hunan Dongting Pharmaceutical (CN) Business Overview Table 100. Hunan Dongting Pharmaceutical (CN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio Table 102. Hunan Dongting Pharmaceutical (CN) Recent Development Table 103. Jewim Pharmaceutical (Shandong) Company Information Table 104. Jewim Pharmaceutical (Shandong) Business Overview Table 105. Jewim Pharmaceutical (Shandong) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio Table 107. Jewim Pharmaceutical (Shandong) Recent Development Table 108. Lundbeck (DK) Company Information Table 109. Lundbeck (DK) Business Overview Table 110. Lundbeck (DK) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Lundbeck (DK) Escitalopram Product Portfolio Table 112. Lundbeck (DK) Recent Development Table 113. Lupin (IN) Company Information Table 114. Lupin (IN) Business Overview Table 115. Lupin (IN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Lupin (IN) Escitalopram Product Portfolio Table 117. Lupin (IN) Recent Development Table 118. Macleods Pharmaceuticals (IN) Company Information Table 119. Macleods Pharmaceuticals (IN) Business Overview Table 120. Macleods Pharmaceuticals (IN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio Table 122. Macleods Pharmaceuticals (IN) Recent Development Table 123. Silarx Pharmacueticals (US) Company Information Table 124. Silarx Pharmacueticals (US) Business Overview Table 125. Silarx Pharmacueticals (US) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Silarx Pharmacueticals (US) Escitalopram Product Portfolio Table 127. Silarx Pharmacueticals (US) Recent Development Table 128. TEVA (Israel) Company Information Table 129. TEVA (Israel) Business Overview Table 130. TEVA (Israel) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. TEVA (Israel) Escitalopram Product Portfolio Table 132. TEVA (Israel) Recent Development Table 133. Xidian Pharmaceutical (CN) Company Information Table 134. Xidian Pharmaceutical (CN) Business Overview Table 135. Xidian Pharmaceutical (CN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Xidian Pharmaceutical (CN) Escitalopram Product Portfolio Table 137. Xidian Pharmaceutical (CN) Recent Development Table 138. Zhejiang Conba Pharmaceutical (CN) Company Information Table 139. Zhejiang Conba Pharmaceutical (CN) Business Overview Table 140. Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio Table 142. Zhejiang Conba Pharmaceutical (CN) Recent Development Table 143. Mylan (US) Company Information Table 144. Mylan (US) Business Overview Table 145. Mylan (US) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Mylan (US) Escitalopram Product Portfolio Table 147. Mylan (US) Recent Development Table 148. Novartis (US) Company Information Table 149. Novartis (US) Business Overview Table 150. Novartis (US) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Novartis (US) Escitalopram Product Portfolio Table 152. Novartis (US) Recent Development Table 153. Sichuan Kelun Pharmaceutical (CN) Company Information Table 154. Sichuan Kelun Pharmaceutical (CN) Business Overview Table 155. Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio Table 157. Sichuan Kelun Pharmaceutical (CN) Recent Development Table 158. Xian Janssen Pharmaceutical (CN) Company Information Table 159. Xian Janssen Pharmaceutical (CN) Business Overview Table 160. Xian Janssen Pharmaceutical (CN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio Table 162. Xian Janssen Pharmaceutical (CN) Recent Development Table 163. Zhejiang Huahai Pharmaceutical (CN) Company Information Table 164. Zhejiang Huahai Pharmaceutical (CN) Business Overview Table 165. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio Table 167. Zhejiang Huahai Pharmaceutical (CN) Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Escitalopram Distributors List Table 171. Escitalopram Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Escitalopram Product Image Figure 2. Global Escitalopram Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Escitalopram Market Size (2021-2032) & (US$ Million) Figure 4. Global Escitalopram Sales (2021-2032) & (K Units) Figure 5. Global Escitalopram Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Escitalopram Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tablets Image Figure 9. Solution Image Figure 10. Global Escitalopram Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Escitalopram Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Escitalopram Sales Market Share by Type (2021-2032) Figure 13. Global Escitalopram Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Escitalopram Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Escitalopram Revenue Market Share by Type (2021-2032) Figure 16. Retail Pharmacies Image Figure 17. Online Pharmacies Image Figure 18. Hospital Pharmacies Image Figure 19. Global Escitalopram Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Escitalopram Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Escitalopram Sales Market Share by Application (2021-2032) Figure 22. Global Escitalopram Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Escitalopram Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Escitalopram Revenue Market Share by Application (2021-2032) Figure 25. North America Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Escitalopram Sales Market Share by Country (2021-2032) Figure 27. U.S. Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Escitalopram Sales Market Share by Country (2021-2032) Figure 32. Germany Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Escitalopram Sales Market Share by Country (2021-2032) Figure 39. China Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Escitalopram Sales Market Share by Country (2021-2032) Figure 47. Brazil Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Escitalopram Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Escitalopram Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Escitalopram Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Escitalopram Revenue (2021-2032) & (US$ Million) Figure 58. North America Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Escitalopram Revenue (2021-2032) & (US$ Million) Figure 60. Europe Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Escitalopram Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Escitalopram Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Escitalopram Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Escitalopram Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Solution
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Accord Healthcare (IN)
  • Amneal Pharmaceuticals (US)
  • Apotex (CA)
  • Aurobindo Pharma (IN)
  • Forest Laboratories (US)
  • Hetero Drugs (IN)
  • Hikma Pharmaceuticals (UK)
  • Hunan Dongting Pharmaceutical (CN)
  • Jewim Pharmaceutical (Shandong)
  • Lundbeck (DK)
  • Lupin (IN)
  • Macleods Pharmaceuticals (IN)
  • Silarx Pharmacueticals (US)
  • TEVA (Israel)
  • Xidian Pharmaceutical (CN)
  • Zhejiang Conba Pharmaceutical (CN)
  • Mylan (US)
  • Novartis (US)
  • Sichuan Kelun Pharmaceutical (CN)
  • Xian Janssen Pharmaceutical (CN)
  • Zhejiang Huahai Pharmaceutical (CN)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Escitalopram Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Escitalopram Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Escitalopram Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Escitalopram Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Escitalopram Market Dynamics
  1. 2.1 Escitalopram Industry Trends
  2. 2.2 Escitalopram Industry Drivers
  3. 2.3 Escitalopram Industry Opportunities and Challenges
  4. 2.4 Escitalopram Industry Restraints
3 Escitalopram Market by Manufacturers
  1. 3.1 Global Escitalopram Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Escitalopram Sales by Manufacturers (2021-2026)
  3. 3.3 Global Escitalopram Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Escitalopram Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Escitalopram Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Escitalopram Manufacturers, Product Type & Application
  7. 3.7 Global Escitalopram Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Escitalopram Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Escitalopram Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Escitalopram Tier 1, Tier 2, and Tier 3
4 Escitalopram Market by Type
  1. 4.1 Escitalopram Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Solution
  4. 4.2 Global Escitalopram Sales by Type
  5. 4.2.1 Global Escitalopram Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Escitalopram Sales by Type (2021-2032)
  7. 4.2.3 Global Escitalopram Sales Market Share by Type (2021-2032)
  8. 4.3 Global Escitalopram Revenue by Type
  9. 4.3.1 Global Escitalopram Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Escitalopram Revenue by Type (2021-2032)
  11. 4.3.3 Global Escitalopram Revenue Market Share by Type (2021-2032)
5 Escitalopram Market by Application
  1. 5.1 Escitalopram Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Escitalopram Sales by Application
  6. 5.2.1 Global Escitalopram Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Escitalopram Sales by Application (2021-2032)
  8. 5.2.3 Global Escitalopram Sales Market Share by Application (2021-2032)
  9. 5.3 Global Escitalopram Revenue by Application
  10. 5.3.1 Global Escitalopram Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Escitalopram Revenue by Application (2021-2032)
  12. 5.3.3 Global Escitalopram Revenue Market Share by Application (2021-2032)
6 Global Escitalopram Sales by Region
  1. 6.1 Global Escitalopram Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Escitalopram Sales by Region (2021-2032)
  3. 6.2.1 Global Escitalopram Sales by Region (2021-2026)
  4. 6.2.2 Global Escitalopram Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Escitalopram Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Escitalopram Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Escitalopram Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Escitalopram Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Escitalopram Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Escitalopram Revenue by Region
  1. 7.1 Global Escitalopram Revenue by Region
  2. 7.1.1 Global Escitalopram Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Escitalopram Revenue by Region (2021-2026)
  4. 7.1.3 Global Escitalopram Revenue by Region (2027-2032)
  5. 7.1.4 Global Escitalopram Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Escitalopram Revenue (2021-2032)
  8. 7.2.2 North America Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Escitalopram Revenue (2021-2032)
  11. 7.3.2 Europe Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Escitalopram Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Escitalopram Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Escitalopram Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare (IN)
  2. 8.1.1 Accord Healthcare (IN) Company Information
  3. 8.1.2 Accord Healthcare (IN) Business Overview
  4. 8.1.3 Accord Healthcare (IN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare (IN) Escitalopram Product Portfolio
  6. 8.1.5 Accord Healthcare (IN) Recent Developments
  7. 8.2 Amneal Pharmaceuticals (US)
  8. 8.2.1 Amneal Pharmaceuticals (US) Company Information
  9. 8.2.2 Amneal Pharmaceuticals (US) Business Overview
  10. 8.2.3 Amneal Pharmaceuticals (US) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals (US) Escitalopram Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals (US) Recent Developments
  13. 8.3 Apotex (CA)
  14. 8.3.1 Apotex (CA) Company Information
  15. 8.3.2 Apotex (CA) Business Overview
  16. 8.3.3 Apotex (CA) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Apotex (CA) Escitalopram Product Portfolio
  18. 8.3.5 Apotex (CA) Recent Developments
  19. 8.4 Aurobindo Pharma (IN)
  20. 8.4.1 Aurobindo Pharma (IN) Company Information
  21. 8.4.2 Aurobindo Pharma (IN) Business Overview
  22. 8.4.3 Aurobindo Pharma (IN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aurobindo Pharma (IN) Escitalopram Product Portfolio
  24. 8.4.5 Aurobindo Pharma (IN) Recent Developments
  25. 8.5 Forest Laboratories (US)
  26. 8.5.1 Forest Laboratories (US) Company Information
  27. 8.5.2 Forest Laboratories (US) Business Overview
  28. 8.5.3 Forest Laboratories (US) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Forest Laboratories (US) Escitalopram Product Portfolio
  30. 8.5.5 Forest Laboratories (US) Recent Developments
  31. 8.6 Hetero Drugs (IN)
  32. 8.6.1 Hetero Drugs (IN) Company Information
  33. 8.6.2 Hetero Drugs (IN) Business Overview
  34. 8.6.3 Hetero Drugs (IN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hetero Drugs (IN) Escitalopram Product Portfolio
  36. 8.6.5 Hetero Drugs (IN) Recent Developments
  37. 8.7 Hikma Pharmaceuticals (UK)
  38. 8.7.1 Hikma Pharmaceuticals (UK) Company Information
  39. 8.7.2 Hikma Pharmaceuticals (UK) Business Overview
  40. 8.7.3 Hikma Pharmaceuticals (UK) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio
  42. 8.7.5 Hikma Pharmaceuticals (UK) Recent Developments
  43. 8.8 Hunan Dongting Pharmaceutical (CN)
  44. 8.8.1 Hunan Dongting Pharmaceutical (CN) Company Information
  45. 8.8.2 Hunan Dongting Pharmaceutical (CN) Business Overview
  46. 8.8.3 Hunan Dongting Pharmaceutical (CN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio
  48. 8.8.5 Hunan Dongting Pharmaceutical (CN) Recent Developments
  49. 8.9 Jewim Pharmaceutical (Shandong)
  50. 8.9.1 Jewim Pharmaceutical (Shandong) Company Information
  51. 8.9.2 Jewim Pharmaceutical (Shandong) Business Overview
  52. 8.9.3 Jewim Pharmaceutical (Shandong) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio
  54. 8.9.5 Jewim Pharmaceutical (Shandong) Recent Developments
  55. 8.10 Lundbeck (DK)
  56. 8.10.1 Lundbeck (DK) Company Information
  57. 8.10.2 Lundbeck (DK) Business Overview
  58. 8.10.3 Lundbeck (DK) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lundbeck (DK) Escitalopram Product Portfolio
  60. 8.10.5 Lundbeck (DK) Recent Developments
  61. 8.11 Lupin (IN)
  62. 8.11.1 Lupin (IN) Company Information
  63. 8.11.2 Lupin (IN) Business Overview
  64. 8.11.3 Lupin (IN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lupin (IN) Escitalopram Product Portfolio
  66. 8.11.5 Lupin (IN) Recent Developments
  67. 8.12 Macleods Pharmaceuticals (IN)
  68. 8.12.1 Macleods Pharmaceuticals (IN) Company Information
  69. 8.12.2 Macleods Pharmaceuticals (IN) Business Overview
  70. 8.12.3 Macleods Pharmaceuticals (IN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio
  72. 8.12.5 Macleods Pharmaceuticals (IN) Recent Developments
  73. 8.13 Silarx Pharmacueticals (US)
  74. 8.13.1 Silarx Pharmacueticals (US) Company Information
  75. 8.13.2 Silarx Pharmacueticals (US) Business Overview
  76. 8.13.3 Silarx Pharmacueticals (US) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Silarx Pharmacueticals (US) Escitalopram Product Portfolio
  78. 8.13.5 Silarx Pharmacueticals (US) Recent Developments
  79. 8.14 TEVA (Israel)
  80. 8.14.1 TEVA (Israel) Company Information
  81. 8.14.2 TEVA (Israel) Business Overview
  82. 8.14.3 TEVA (Israel) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 TEVA (Israel) Escitalopram Product Portfolio
  84. 8.14.5 TEVA (Israel) Recent Developments
  85. 8.15 Xidian Pharmaceutical (CN)
  86. 8.15.1 Xidian Pharmaceutical (CN) Company Information
  87. 8.15.2 Xidian Pharmaceutical (CN) Business Overview
  88. 8.15.3 Xidian Pharmaceutical (CN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Xidian Pharmaceutical (CN) Escitalopram Product Portfolio
  90. 8.15.5 Xidian Pharmaceutical (CN) Recent Developments
  91. 8.16 Zhejiang Conba Pharmaceutical (CN)
  92. 8.16.1 Zhejiang Conba Pharmaceutical (CN) Company Information
  93. 8.16.2 Zhejiang Conba Pharmaceutical (CN) Business Overview
  94. 8.16.3 Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio
  96. 8.16.5 Zhejiang Conba Pharmaceutical (CN) Recent Developments
  97. 8.17 Mylan (US)
  98. 8.17.1 Mylan (US) Company Information
  99. 8.17.2 Mylan (US) Business Overview
  100. 8.17.3 Mylan (US) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Mylan (US) Escitalopram Product Portfolio
  102. 8.17.5 Mylan (US) Recent Developments
  103. 8.18 Novartis (US)
  104. 8.18.1 Novartis (US) Company Information
  105. 8.18.2 Novartis (US) Business Overview
  106. 8.18.3 Novartis (US) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Novartis (US) Escitalopram Product Portfolio
  108. 8.18.5 Novartis (US) Recent Developments
  109. 8.19 Sichuan Kelun Pharmaceutical (CN)
  110. 8.19.1 Sichuan Kelun Pharmaceutical (CN) Company Information
  111. 8.19.2 Sichuan Kelun Pharmaceutical (CN) Business Overview
  112. 8.19.3 Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio
  114. 8.19.5 Sichuan Kelun Pharmaceutical (CN) Recent Developments
  115. 8.20 Xian Janssen Pharmaceutical (CN)
  116. 8.20.1 Xian Janssen Pharmaceutical (CN) Company Information
  117. 8.20.2 Xian Janssen Pharmaceutical (CN) Business Overview
  118. 8.20.3 Xian Janssen Pharmaceutical (CN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio
  120. 8.20.5 Xian Janssen Pharmaceutical (CN) Recent Developments
  121. 8.21 Zhejiang Huahai Pharmaceutical (CN)
  122. 8.21.1 Zhejiang Huahai Pharmaceutical (CN) Company Information
  123. 8.21.2 Zhejiang Huahai Pharmaceutical (CN) Business Overview
  124. 8.21.3 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio
  126. 8.21.5 Zhejiang Huahai Pharmaceutical (CN) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Escitalopram Value Chain Analysis
  2. 9.1.1 Escitalopram Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Escitalopram Production Mode & Process
  6. 9.2 Escitalopram Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Escitalopram Distributors
  9. 9.2.3 Escitalopram Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst